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Introduction

https://www.toothclub.gov.hk/e
n/pnc/en_pnc_2_2_1_6.html

The Problem
●
●

●
●
●

Normal periodontal tissue - homeostasis
is maintained by bone resorbing
osteoclasts
Patients with osteoporosis - impaired
homeostasis

NF-KB Ligand (RANKL)
Osteoblasts produce osteoprotegerin
(OPG)
**OPG is protective against bone loss**

https://www.medicinenet.com/osteop
orosis/article.htm

Reveromycin A osteoclast activity
suppressor

https://www.caymanchem.com/product/1
7458/reveromycin-a
- 3 carboxylic acids

Taken up by acid-secreting
osteoclasts
Induces apoptosis in these cells

Inhibits bone resorption

Previous Study
Periodontal disease was induced in OPG KO mouse model and found
intraperitoneally administered RMA inhibited alveolar bone
resorption
Researchers wanted to see if RMA could be administered
non-invasively through the mouth

OPG KO osteoprotegerin
knockout
(osteoprotegerin has
been removed from
mice)
RMA - reveromycin A
Intraperitoneally through the stomach

Question to be answered:
RMA - reveromycin A

Does RMA ointment reduce the number of osteoclasts and
inhibit bone resorption in mice with periodontal disease?

Materials and Methods

-

-

64, 8-week old male wild type and OPG KO experimented on in
temperature maintained conditions with constant light cycles.
They had free access to food and water
Periodontal diseased mice were prepared through ligation by
placing wire as shown:

OPG KO osteoprotegerin
knockout
(osteoprotegerin has
been removed from
mice)
RMA - reveromycin A
Ligation - surgical
closing off of blood
vessel

-

Silicone -based ointment with 1%
RMA was used
Same ointment without RMA was
used for control group
Ointment was applied three times
daily at:

RMA - reveromycin A

WT - wild type

Experimental Groups

OPG KO osteoprotegerin
knockout
(osteoprotegerin has
been removed from
mice)

WC OC

WR- OR-

WR+ OR+

WT and OPG KO

WT and OPG KO

WT and OPG KO

mice without

mice with ligature

mice with ligature

RMA - reveromycin A

ligature or RMA

and without RMA

and RMA

Ligation - surgical
closing off of blood
vessel

-

Mice were sacriﬁced 8 weeks after ligature
Samples were examined using micro-computed
tomography (u-CT)
Alveolar bone volume was analyzed using TRI/3D BON
software
% of remaining alveolar bone was calculated as shown:

Ligation - surgical
closing off of blood
vessel

-

-

Maxillae were collected and ﬁxed in 10% neutral buffered
formalin, then decalciﬁed in 10% EDTA for 4 weeks
Parafﬁn blocks were prepared and tissue observation
sites were selected based on where molar roots were
found
Hematoxylin-eosin (H&E) staining was performed
% attachment was determined using:

-

TRAP stain was also performed

-

Maxilla - upper ﬁxed
bone of jaw
H&E - provides
detailed view of the
tissue
TRAP - checks for
reduced resorptive
activity

-

-

Tnf-a and IL-1B immunostaining was performed
- Stained sections were scored as follows:
- 1 (0-20% positive staining)
- 2 (21-40% positive staining)
- 3 (41-60% positive staining)
- 4 (>60% positive staining)
Slides were evaluated by 2 different examiners

Tnf-a and IL-1B - used
for checking cell
responses (like
apoptosis)

WT - wild type

Side Question: Does swallowing excess RMA
ointment have an eﬀect?
-

-

4 groups - ointment free, peroral administration, local
administration with non-RMA ointment, local
administration with RMA ointment
WT and OPG KO mice used
Blood samples collected and TRAP concentrations were
measured using ELISA kit

OPG KO osteoprotegerin
knockout
(osteoprotegerin has
been removed from
mice)
RMA - reveromycin A
TRAP - checks for
reduced resorptive
activity

Results

u-CT- micro-computed
tomography

Comparison
of u-CT

WC and OC - wild
type and OPG KO
mice w/o ligation or
RMA
WR- and OR- : wild
type and OPG KO
mice w/ ligation and
w/o RMA
WR+ and OR+: wild
type and OPG KO
mice w/ ligation and
RMA

H&E - provides
detailed view of the
tissue

H&E
staining and
attachment
level

WC and OC - wild
type and OPG KO
mice w/o ligation or
RMA
WR- and OR- : wild
type and OPG KO
mice w/ ligation and
w/o RMA
WR+ and OR+: wild
type and OPG KO
mice w/ ligation and
RMA

Osteoclast
Count

WC and OC - wild
type and OPG KO
mice w/o ligation or
RMA
WR- and OR- : wild
type and OPG KO
mice w/ ligation and
w/o RMA
WR+ and OR+: wild
type and OPG KO
mice w/ ligation and
RMA

Tnf-a and IL-1B - used
for checking cell
responses (like
apoptosis)

TnF-a
and
IL-1B

WC and OC - wild
type and OPG KO
mice w/o ligation or
RMA
WR- and OR- : wild
type and OPG KO
mice w/ ligation and
w/o RMA
WR+ and OR+: wild
type and OPG KO
mice w/ ligation and
RMA

WT - wild type

Results of side
question

OPG KOosteoprotegerin
knockout
p.o. - peroral
LA - topical
administration

Discussion

WR+ and OR+ had smaller attachment
loss than WR- and ORRMA ointment reduced immunostaining
scores of TNF-a and IL-1B

-

-

RMA-containing ointment inhibited alveolar
bone resorption and alleviated periodontal
disease progression
RMA locally suppressed inﬂammation

RMA ointment suppressed localized inﬂammation and alveolar bone resorption and
decreased osteoclast count to a similar degree as it had when administered
peritoneally
These results suggest the effectiveness of RMA in treating patients with vulnerable
periodontal tissue due to periodontitis and osteoporosis

What’s currently being used and why is RMA better?

Final Conclusion
The study shows that RMA is an eﬀective
non-invasive treatment for:
- Preventing periodontitis
- Inhibiting alveolar bone resorption locally

Link:: https://www.sciencedirect.com/science/article/pii/S1347861321000530

